Laurion Capital Management’s Cascadian Therapeutics, Inc. CASC Stock Holding History

Laurion Capital Management’s Portfolio CASC Stock Details CASC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-260,710	Closed	-$965K	–	1899
2017 Q4	$965K	Buy	+260,710	New	+$1.07M	﹤0.01%	977
2016 Q3	–	Sell	-45,517	Closed	-$258K	–	1204
2016 Q2	$258K	Buy	+45,517	New	+$309K	﹤0.01%	685

Laurion Capital Management's CASC Position: Q1 2018 in Review

Laurion Capital Management sold out of Cascadian Therapeutics, Inc. (CASC) in Q1 2018, closing a stake of 260,710 shares — an estimated $965K sold.

Laurion Capital Management first reported a position in CASC in Q2 2016 and held it in 2 quarters. The position peaked at $965K in Q4 2017. 1 fund tracked by Wall St. Rank holds CASC as of Q1 2018.

Laurion Capital Management reported no remaining Cascadian Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
Laurion Capital Management sold 260,710 Cascadian Therapeutics, Inc. shares in Q1 2018, an estimated $965K.
Laurion Capital Management first reported a position in Cascadian Therapeutics, Inc. in Q2 2016 and held it in 2 quarters.
Laurion Capital Management's Cascadian Therapeutics, Inc. position peaked at $965K in Q4 2017.
1 fund tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q1 2018.

Based on Laurion Capital Management's 13F filing for Q1 2018, filed 14 May 2018.